For 200 years, medicine has been built for the average patient.

There is no average patient.

First Dose predicts how an individual will respond to a medication before the first prescription, so patients get the right drug, at the right dose, the first time. Starting with GLP-1s. Built for every drug class.

Partner with us Learn more

Currently piloting with

How it works

How First Dose works

One pipeline, three stages: from raw patient signals to a prescription a clinician can act on.

STEP 01

Personalized Intake

Adaptive assessment to identify your biological brakes and therapeutic accelerators — creates a personalized Dose Readiness Report.

What it covers

Safety screening
Nausea sensitivity
Appetite signals
GI baseline
Mood & autonomic flags
Prior GLP-1 response

Start Intake

STEP 02

Clinician Portal

Review patient data, risk profiles, and Dose Readiness signals to approve or adjust weekly dose escalations.

Clinician tools

Dose Readiness Report
Risk flag review
Weekly escalation approval
Patient timeline

Open Dashboard

STEP 03

Patient Management

Track injections, log weekly weight, report side effects, and see your dose-pacing timeline update in real time.

Patient features

Injection tracking
Weekly weight log
Side-effect check-in
Dose-pacing timeline

Open Patient App

Starting with GLP-1s. Built for every drug class.

Built on real science

First Dose is built by researchers, validated by clinicians, and trusted by the institutions that set the standard for drug development.

Early data from our clinic pilots is validating what the science predicted. More to come.

Advisory board from

Bristol Myers SquibbJohnson & JohnsonGSK

Dr. Chowdari

Bristol Myers Squibb

Drug development and clinical pharmacology

Dr. Eltepu

Johnson & Johnson

Precision medicine and regulatory strategy

Dr. Peddi

GSK

Pharmacogenomics and therapeutic response

Our research

We've been doing work in this space for 6+ years.

We write about what we learn at sideeffect.me.

Read the blog →

One platform

One platform. Every medication.

We're starting where the evidence is strongest and the need is most urgent. The rest is coming.

GLP-1s

Live

The fastest growing drug class in America. The highest discontinuation rate of any medication. 9 in 10 patients don't complete their first year. Side effects, wrong dosing, wrong patient. First Dose predicts individual response before the first prescription, so your patients stay on therapy.

Learn more →

Antidepressants

Coming soon

1 in 3 patients don't respond to their first antidepressant. Most wait months to find out. Pharmacogenomic-guided prescribing increases remission rates by 58% at 8 weeks. The data exists. The application doesn't. Yet.

Cardiovascular

Coming soon

Cardiovascular care still runs on population averages. The breakthrough isn't a new drug. It's understanding each person well enough that the right prevention and the right dose stop being guesswork. We're building that precision for every clinic.

Oncology

Coming soon

In cancer treatment, the wrong drug isn't an inconvenience. It's a lost window. Pharmacogenomics has the strongest evidence base in all of medicine here. We're making precision response prediction universal.

The next frontier of medicine isn't a new drug. It's understanding each human being at a biological level with enough depth that disease becomes predictable, treatment becomes personal, and the question of how to live longer finally has a real answer.

Medicine has treated populations for 200 years. We're building the infrastructure to treat individuals. If that matters to you, let's talk.

For clinics

Reduce side effects. Improve retention. Prescribe with precision. Join the growing number of telehealth providers using First Dose to match patients to the right medication before they take it.

Partner with First Dose →

For investors & partners

The precision layer for medicine doesn't exist yet. We're building it, starting with the drug decision, expanding to the full picture of individual health. If you want to be part of that, we want to hear from you.

Get in touch →